MAUDE Adverse Event Report: TEDEC-MEIJI FARMA GENVISC 850; ACID, HYALURONIC, INTRAARTICULAR

Lot Number J1

Device Problem No Apparent Adverse Event (3189)

Patient Problems Pain (1994); Arthralgia (2355); Joint Swelling (2356)

Event Date 09/26/2016

Event Type  Injury  

Manufacturer Narrative

Suspect medical device, genvisc 850 sodium hyaluronate (ha) 10 mg/ml with a (b)(4), was manufactured, tested and released by (b)(4) according to fda approved processes and specifications.(b)(4), as part of the release of the product to the us market and additionally when evaluating this case, reviewed product components-release documentation (e.G.Bulk ha and syringe primary package, among others) as well as manufacturing batch records, product testing, and release documentation.In addition, as part the device design shipping study protocol, upon product arrival to the warehouse, in (b)(4), genvisc 850 was retested for ha content and for sterility.Through out these series of evaluations, genvisc 850 complied with all the requirements of sterility, ha content as well as all the other specification required for release of the product to the us market.No findings were observed that would indicate that there is and issue with the suspect medical device in relation to product manufacturing process and release compliance.

Event Description

Provider clinic reported to (b)(4) that a left knee effusion occurred after 2nd genvisc 850 injection given on (b)(6) 2016.Ae assessor spoke with clinical operations manager for further investigation of this case.Pt.Visited clinic for consultation on (b)(6) 2016 for complaint of bilateral knee pain; pt.Has a past medical history of oa.Pt.Began bilateral knee injections with genvisc 850 on (b)(6) 2016 with rated pain 3-4/10 with increased pain while walking, standing and sitting for long periods.Second injection of genvisc 850 given in right knee on (b)(6) 2016 with rated pain of 4/10.Second injection of genvisc 850 left knee given (b)(6) 2016 with rated pain of 4/10.Third right knee injection of genvisc 850 was given (b)(6) 2016 with rated pain of 3-4/10, however, pt.Complained of increased pain in left knee rated 10/10 with an effusion present; 28 cc of clear liquid aspirated.Kenalog was given by injection into left knee cavity.No clinic note about ultrasound being performed.Third injection of genvisc 850 left knee given (b)(6) 2016 with verbal indication of improvement in function and rated pain 2-3/10.Fourth injection of genvisc 850 into right knee was given (b)(6) 2016 with improvement in walking and rated pain 4/10.Fourth injection of genvisc 850 into left knee given (b)(6) 2016 with less pain while walking and rated pain as 4/10.Fifth injection of genvisc 850 was given into right knee on (b)(6) 2016 with less pain while walking and rated pain as 4/10.Final and fifth injection of genvisc 850 given into left knee with less pain while walking and rated pain as 4/10.The pt.Had less pain while walking and increased functionality after completing genvisc 850 injections.The clinic indicated the effusion resolved without issue.The effusion is likely a contributing factor to the reported increased pain but the causal role of the osteoarthritis disease cannot be excluded.Genvisc 850 injection cannot be excluded as a contributing factor to the left knee effusion.This case will be closed without further follow-up from the ae assessor; no remedial action required.This case will be closed as serious due to the report of the left knee effusion.Provider clinic operations manager reports that the clinic does not send fluid from knee aspirations out for evaluation, if the fluid is clear.

• Brand Name: GENVISC 850
• Type of Device: ACID, HYALURONIC, INTRAARTICULAR
• Manufacturer (Section D): TEDEC-MEIJI FARMA; ctra. m-300, km 30, 500; alcala de henares (madrid), 28802 ; SP 28802
• Manufacturer (Section G): TEDEC-MEIJI FARMA; ctra. m-300, km 30,500; alcala de henares, madrid 28802 ; SP 28802
• Manufacturer Contact: celia vazquez lopez ; ctra. m-300, km 30, 500; alcala de henares, madrid 28802 ; SP 28802 ; 18870980
• MDR Report Key: 6231318
• MDR Text Key: 64125760
• Report Number: 3003184440-2017-00001
• Device Sequence Number: 1
• Product Code: MOZ
• UDI-Device Identifier: 00850653006016
• UDI-Public: (01)00850653006016(17)180630(10)J1
• Combination Product (y/n): N
• Reporter Country Code: US
• PMA/PMN Number: P140005
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: distributor
• Reporter Occupation: Physician
• Type of Report: Initial
• Report Date: 01/06/2017,10/13/2016

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 01/06/2017
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Expiration Date: 06/30/2018
• Device Lot Number: J1
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Was the Report Sent to FDA?: Yes
• Date Report Sent to FDA: 01/06/2017
• Distributor Facility Aware Date: 10/13/2016
• Device Age: 1 HR
• Event Location: Home
• Date Report to Manufacturer: 10/13/2016
• Date Manufacturer Received: 10/13/2016
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Date Device Manufactured: 06/19/2015
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Age: 84 YR
• Patient Weight: 54